EndoChoice Holdings, Inc. announced today that William (Bill) R. Enquist, former President of Global Endoscopy for Stryker Corporation, and David (Dave) H. Mowry, President and CEO of Tornier N.V. will join the EndoChoice Board of Directors effective September 9, 2015.

Since the successful completion of its initial public offering on the NYSE in June 2015, EndoChoice has moved to bolster its Board with seasoned leaders known within the medical device industry for their experience with high growth organizations. Mr. Enquist joined Stryker in 1986 and rose through the sales and marketing ranks until being appointed President of Global Endoscopy in 1998. Under his leadership over the next 16 years Global Endoscopy revenues grew to over $1 Billion before his retirement in 2013. 

Mr. Mowry has more than 27 years of operations experience in the medical device industry including the areas of manufacturing, logistics, quality assurance and general management. He has served as President and CEO of Tornier since 2012, after having previously held executive positions at Covidien, ev3, and Zimmer.

"We are pleased to be able to add leaders of Bill and Dave's caliber to our Board," said Mark Gilreath, Founder and CEO of EndoChoice.  "Our company has historically grown revenues more than 30% each year and as we continue to seek that type of growth, we will benefit from the insights of others who have traveled down similar paths with publicly traded firms."

"Both Bill and Dave will provide wisdom on expanding our sales and marketing capabilities and scaling our quality manufacturing systems," Mr. Gilreath added. "Since the beginning of 2015, we have released the 2^nd generation of our Fuse®, Full Spectrum Endoscopy® System, multiple new products in our single-use product portfolio and new services within our pathology business.

With the additions of Mr. Enquist and Mr. Mowry to the Board, current directors Dr. Uri Geiger and Rurik Vandevenne have announced that they do not intend to stand for re-election at the Company's 2016 annual stockholders meeting following the expiration of their current terms.